Under the terms of the agreement, Rib-X and the Molecular Biology of the Medical Research Council (MRC) will continue to jointly explore the high resolution crystal structure of the 70S ribosome.
Erin Duffy, vice president of structure-based drug design at Rib-X, said: “Using information discovered about the ribosome during our first year of work with the MRC, Rib-X has been able to advance the iterative intelligent discovery engine that the company developed to design novel antibiotic scaffolds which circumvent the mechanisms employed by resistant bacteria.”